TARA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.352

-18.02%

-0.362

+25%

-0.357

+2.14%

Estimates Revision

The market is revising No Change the revenue expectations for Protara Therapeutics, Inc. (TARA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 2.67%.

EPS Estimates for FY2025

Revise Downward

-8.95%

In Past 3 Month

Stock Price

Go Up

+2.67%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast TARA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARA is 23.33 USD with a low forecast of 21.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

21.00

Averages

23.33

High

26.00

Current: 0.000

Low

21.00

Averages

23.33

High

26.00

Piper Sandler

Overweight

initiated

$24

2026-01-07

New

Reason

Piper Sandler

Price Target

$24

2026-01-07

New

initiated

Overweight

Reason

Piper Sandler initiated coverage of Protara Therapeutics with an Overweight rating and $24 price target. The company is "under-the-radar" despite being a clinical stage biotech with three "potentially substantial and unique market opportunities," the analyst tells investors in a research note.

JonesResearch

Soumit Roy

Buy

initiated

$21

2025-05-22

Reason

JonesResearch

Soumit Roy

Price Target

$21

2025-05-22

initiated

Buy

Reason

JonesResearch analyst Soumit Roy initiated coverage of Protara Therapeutics with a Buy rating and $21 price target. The stock is currently trading at cash value, the analyst tells investors in a research note. The firm says Protara has three diverse, late-stage clinical programs, two of which are "fairly de-risked."

Scotiabank

George Farmer

Buy

Initiates

$12

2025-04-16

Reason

Scotiabank

George Farmer

Price Target

$12

2025-04-16

Initiates

Buy

Reason

Scotiabank analyst George Farmer initiated coverage of Protara Therapeutics with an Outperform rating and $12 price target. The company is developing a novel treatment for nonmuscle invasive bladder cancer, which the firm believes represents a "massive commercial opportunity," the analyst tells investors. As of now, no therapeutic approach stands out to us as a particular winner, which the firm thinks will be driving investor debate through 2027, but it believes the NMIBC market, which is "just beginning to be meaningfully tapped, could generate billions of dollars in sales over the next decade.

Cantor Fitzgerald

Li Watsek

Buy

Initiates

n/a

2025-03-14

Reason

Cantor Fitzgerald

Li Watsek

Price Target

n/a

2025-03-14

Initiates

Buy

Reason

Cantor Fitzgerald analyst Li Watsek initiated coverage of Protara Therapeutics with an Overweight rating.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$23

2025-03-06

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$23

2025-03-06

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Protara Therapeutics Inc (TARA.O) is -3.78, compared to its 5-year average forward P/E of -1.68. For a more detailed relative valuation and DCF analysis to assess Protara Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.68

Current PE

-3.78

Overvalued PE

-0.66

Undervalued PE

-2.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.07

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.75

Undervalued EV/EBITDA

-0.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

6.61

Current PS

0.00

Overvalued PS

36.10

Undervalued PS

-22.87

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TARA News & Events

Events Timeline

No data

News

9.0

14:03 PMNASDAQ.COM

ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis

9.0

01-07NASDAQ.COM

Protara Doses First Patient in Pivotal THRIVE-3 Trial for IV Choline Chloride

9.0

01-05Globenewswire

Protara Therapeutics Receives FDA Breakthrough and Fast Track Designations for TARA-002

People Also Watch

Frequently Asked Questions

What is Protara Therapeutics Inc (TARA) stock price today?

The current price of TARA is 5.76 USD — it has increased 2.67 % in the last trading day.

What is Protara Therapeutics Inc (TARA)'s business?

Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

What is the price predicton of TARA Stock?

What is Protara Therapeutics Inc (TARA)'s revenue for the last quarter?

Protara Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Protara Therapeutics Inc (TARA)'s earnings per share (EPS) for the last quarter?

Protara Therapeutics Inc. EPS for the last quarter amounts to -0.31 USD, decreased -38.00 % YoY.

What changes have occurred in the market's expectations for Protara Therapeutics Inc (TARA)'s fundamentals?

How many employees does Protara Therapeutics Inc (TARA). have?

Protara Therapeutics Inc (TARA) has 28 emplpoyees as of January 09 2026.

What is Protara Therapeutics Inc (TARA) market cap?

Today TARA has the market capitalization of 300.62M USD.